A Ramp Up In Opdivo And Eliquis Sales Will Drive Bristol-Myers Squibb's Future Growth

Bristol-Myers Squibb (NYSE:BMY)recently posted its Q2 results, which topped the Street estimates. The company's overall revenues grew 14%, led by continued ramp up in Opdivo and Eliquis sales. Both of these drugs are on a strong run, and this trend will likely continue in the foreseeable future...